Terms: = Liver cancer AND HER1, YOR227W
19 results:
1. The Effect of Aflatoxin B1 on Tumor-Related Genes and Phenotypic Characters of MCF7 and MCF10A Cells.
Adam MAA; Kamal LZM; Kanakal M; Babu D; Dahham SS; Tabana Y; Lok B; Bermoy BM; Yunus MA; Than LTL; Barakat K; Sandai D
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233156
[TBL] [Abstract] [Full Text] [Related]
2. Based on lapatinib innovative near-infrared fluorescent probes targeting her1/HER2 for in vivo tumors imaging.
Li C; Lin Q; Hu F; Bao R; Cai H; Gu Y
Biosens Bioelectron; 2022 Oct; 214():114503. PubMed ID: 35779413
[TBL] [Abstract] [Full Text] [Related]
3. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
4. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
5. Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform cancer Therapy.
Vasmatzis G; Liu MC; Reganti S; Feathers RW; Smadbeck J; Johnson SH; Schaefer Klein JL; Harris FR; Yang L; Kosari F; Murphy SJ; Borad MJ; Thompson EA; Cheville JC; Anastasiadis PZ
Mayo Clin Proc; 2020 Feb; 95(2):306-318. PubMed ID: 31685261
[TBL] [Abstract] [Full Text] [Related]
6. Neratinib in HER2-Positive Breast cancer Patients.
Paranjpe R; Basatneh D; Tao G; De Angelis C; Noormohammed S; Ekinci E; Abughosh S; Ghose R; Trivedi MV
Ann Pharmacother; 2019 Jun; 53(6):612-620. PubMed ID: 30607980
[TBL] [Abstract] [Full Text] [Related]
7. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
Pellat A; Vaquero J; Fouassier L
Hepatology; 2018 Feb; 67(2):762-773. PubMed ID: 28671339
[TBL] [Abstract] [Full Text] [Related]
8. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?
Göksu SS; Bozcuk H; Koral L; Çakar B; Gündüz S; Tatlı AM; Arslan D; Uysal M; Koçer M; Artaç M; Karabulut B; Coşkun HS; Özdoğan M; Savaş B
Indian J Cancer; 2015; 52(4):517-9. PubMed ID: 26960462
[TBL] [Abstract] [Full Text] [Related]
9. Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder cancer: EORTC Trial 30061.
Cerbone L; Sternberg CN; Sengeløv L; Agerbaek M; Van Herpen C; Marreaud S; Collette S; Zhang J; Daugaard G
Oncology; 2016; 90(1):21-8. PubMed ID: 26468947
[TBL] [Abstract] [Full Text] [Related]
10. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Giri N; Masters JC; Plotka A; Liang Y; Boutros T; Pardo P; O'Connell J; Bello C
Invest New Drugs; 2015 Aug; 33(4):931-41. PubMed ID: 26048096
[TBL] [Abstract] [Full Text] [Related]
11. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract] [Full Text] [Related]
12. High lapatinib plasma levels in breast cancer patients: risk or benefit?
Cizkova M; Bouchalova K; Friedecky D; Polynkova A; Janostakova A; Radova L; Cwiertka K; Trojanec R; Zezulova M; Zlevorova M; Hajduch M; Melichar B
Tumori; 2012; 98(1):162-5. PubMed ID: 22495718
[TBL] [Abstract] [Full Text] [Related]
13. Subacute transient encephalopathy induced by erlotinib.
Okyuama T; Akazawa Y; Uchida J; Nishino K; Kumagai T; Imamura F
Oncol Res; 2011; 19(8-9):399-402. PubMed ID: 22329199
[TBL] [Abstract] [Full Text] [Related]
14. her1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
Nayak TK; Garmestani K; Milenic DE; Baidoo KE; Brechbiel MW
PLoS One; 2011 Mar; 6(3):e18198. PubMed ID: 21464917
[TBL] [Abstract] [Full Text] [Related]
15. Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Suzuki Y; Saito Y; Terao M; Terada M; Morioka T; Tsuda B; Okamura T; Niikura N; Tokuda Y
Tokai J Exp Clin Med; 2010 Dec; 35(4):148-51. PubMed ID: 21319046
[TBL] [Abstract] [Full Text] [Related]
16. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12.
Rigo A; Gottardi M; Zamò A; Mauri P; Bonifacio M; Krampera M; Damiani E; Pizzolo G; Vinante F
Mol Cancer; 2010 Oct; 9():273. PubMed ID: 20946648
[TBL] [Abstract] [Full Text] [Related]
17. [Targeted therapies and their indications in solid neoplasias].
Dreyer C; Raymond E; Faivre S
Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
[TBL] [Abstract] [Full Text] [Related]
18. Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer.
Yamada M; Ichikawa Y; Yamagishi S; Momiyama N; Ota M; Fujii S; Tanaka K; Togo S; Ohki S; Shimada H
Clin Cancer Res; 2008 Apr; 14(8):2351-6. PubMed ID: 18413824
[TBL] [Abstract] [Full Text] [Related]
19. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
[TBL] [Abstract] [Full Text] [Related]
